Irbesartan undergoes metabolism through the CYP2C9 to an inactive metabolite. Hallberg P et al. randomly assigned 115 hypertensive patients to be treated with atenolol or irbesartan. They found that the CYP2C9 genotype predicted the BP response to irbesartan and had no influence on the effect of atenolol.